Last updated: November 2, 2026
Gintuit was a tissue-engineered oral-repair product developed and commercialized by Organogenesis. The FDA approved Gintuit in 2012 through the premarket approval pathway for treating certain mucogingival conditions in adults. Organogenesis later discontinued commercial sales because manufacturing constraints and limited market adoption prevented a viable business case. Gintuit does not have an Orange Book listing, conventional generic-substitution exposure, or a biosimilar pathway. Its commercial value ended primarily through manufacturing and adoption barriers rather than patent expiration.
What is Gintuit and what was its FDA-approved use?
Gintuit is an allogeneic cellularized scaffold containing living human keratinocytes and fibroblasts within a bovine collagen matrix. It was designed for topical application in the oral cavity to treat mucogingival conditions in adults, including localized gingival recession and related soft-tissue defects.
The FDA approved Gintuit under PMA application P110013 on March 9, 2012. The product was regulated as a high-risk medical device and human-cell-containing tissue-engineered product rather than as a conventional prescription drug or biologic licensed under a standard BLA pathway. The FDA approval required manufacturing controls, clinical follow-up, labeling restrictions, and post-approval obligations.[1]
| Product attribute |
Gintuit status |
| Product name |
Gintuit |
| Developer and manufacturer |
Organogenesis Inc. |
| Active biological components |
Allogeneic human keratinocytes and fibroblasts |
| Scaffold |
Bovine collagen matrix |
| Therapeutic area |
Oral surgery, periodontics, mucogingival repair |
| FDA pathway |
Premarket approval, PMA P110013 |
| FDA approval date |
March 9, 2012 |
| Administration |
Topical application in the oral cavity |
| Commercial status |
Sales discontinued |
| Orange Book listing |
None identified |
| Generic drug pathway |
Not applicable |
| Biosimilar pathway |
Not applicable |
When did Gintuit lose exclusivity and when did it leave the market?
Gintuit did not have a conventional small-molecule exclusivity period comparable to five-year new chemical entity exclusivity or a 12-year reference-product biologic exclusivity period. Its regulatory protection came from the PMA approval, manufacturing controls, clinical evidence, and intellectual-property rights rather than from Orange Book exclusivity.
Organogenesis discontinued Gintuit sales and marketing in 2016. The company attributed the decision to manufacturing challenges and limited commercial adoption. Organogenesis continued focusing on its advanced-wound-care and surgical products, including Apligraf, Dermagraft, NuShield, and related offerings.[2]
Gintuit exclusivity and commercial timeline
| Date |
Event |
| 2012 |
FDA approved Gintuit under PMA P110013 |
| 2012-2015 |
Commercial launch and market development |
| 2016 |
Organogenesis discontinued Gintuit sales and marketing |
| 2017 onward |
Gintuit no longer formed part of Organogenesis' active commercial product portfolio |
| Current status |
No active commercial market identified |
The relevant commercial endpoint was product discontinuation, not a patent expiry event. A third party could not simply launch a substitute product by filing an Abbreviated New Drug Application because Gintuit was not an approved conventional drug.
What were the main market barriers for Gintuit?
Gintuit faced a difficult combination of clinical workflow, manufacturing, reimbursement, and adoption barriers.
Manufacturing complexity
Gintuit contained living human cells and required controlled tissue processing, cell expansion, quality testing, storage, and distribution. That manufacturing model is more complex than the production of acellular collagen membranes or synthetic periodontal materials.
The product’s commercial viability depended on maintaining a reliable supply of viable tissue-engineered grafts. Manufacturing deviations, limited production scale, short or constrained shelf-life, and logistics requirements can increase cost per unit and complicate distribution to dental practices.
Procedure economics
Periodontal and mucogingival procedures are often performed in outpatient dental settings with strong sensitivity to product cost and reimbursement. A cellularized scaffold must demonstrate enough clinical and economic value to justify a premium over established alternatives, including:
- Autologous connective-tissue grafting from the patient’s palate.
- Acellular dermal matrices.
- Xenogeneic collagen matrices.
- Synthetic or processed tissue scaffolds.
The competing procedures were familiar to periodontists and could be integrated into existing surgical workflows. Gintuit required clinicians to adopt a newer, more complex tissue-engineered product without a clearly established reimbursement advantage.
Clinical adoption
Gintuit was designed to reduce reliance on autologous tissue harvesting and provide a standardized living graft. The clinical proposition was attractive, but adoption depended on physician training, patient selection, procedural economics, and confidence in handling a living cellular product.
Organogenesis ultimately reported that commercial adoption remained limited. The product therefore lacked the volume required to absorb its manufacturing and commercialization costs.
How did Gintuit compare with competing periodontal products?
Gintuit competed with both surgical techniques and biologic or biomaterial products. Its direct competitive set included acellular dermal matrices such as AlloDerm, xenogeneic collagen matrices such as Geistlich Mucograft, and autologous tissue grafting.
| Option |
Biological composition |
Main commercial advantage |
Main limitation relative to Gintuit |
| Gintuit |
Living human cells on collagen scaffold |
Avoided harvesting a palatal graft and offered a tissue-engineered approach |
Manufacturing complexity, high cost, limited adoption |
| Autologous connective-tissue graft |
Patient-derived tissue |
Established clinical technique and broad familiarity |
Requires donor-site surgery and creates additional morbidity |
| AlloDerm |
Acellular human dermal matrix |
Established soft-tissue substitute with broad surgical use |
Does not contain living expanded cells |
| Geistlich Mucograft |
Porcine collagen matrix |
Simplified handling and off-the-shelf biomaterial model |
No living human cellular component |
| Other collagen membranes |
Xenogeneic or synthetic materials |
Lower complexity and broad availability |
May provide less biological activity than a cellularized construct |
Gintuit’s differentiated value was its living cellular component. That distinction also created its central commercial weakness: the product was more difficult and expensive to manufacture than acellular alternatives.
What was Gintuit’s financial trajectory?
Public filings do not provide a separately reported Gintuit revenue series, gross-margin history, unit volume, or product-level profitability. Organogenesis reported company-level results across broader product categories, and Gintuit was not disclosed as a standalone reporting segment.
The available financial trajectory is therefore operational rather than numerical:
- Organogenesis invested in commercializing Gintuit after FDA approval.
- The product entered a specialized dental and periodontal market.
- Market uptake remained limited.
- Manufacturing challenges impaired the product’s economics.
- Organogenesis discontinued sales and marketing in 2016.
- The company redirected commercial resources toward higher-volume advanced-wound-care and surgical products.
Revenue exposure
Gintuit’s contribution to Organogenesis’ consolidated revenue was not material enough to be separately reported in public company filings. The product’s discontinuation did not threaten the company’s broader commercial platform because Organogenesis had a larger portfolio of wound-care and surgical products.
The financial effect was more likely to involve sunk development costs, inventory and manufacturing impairment, workforce and infrastructure costs, and the loss of prospective revenue than a major decline in consolidated sales. Public filings do not identify a separately quantified Gintuit impairment charge or lost-revenue figure.[2][3]
| Financial metric |
Publicly disclosed Gintuit data |
| Annual product revenue |
Not separately disclosed |
| Gross margin |
Not separately disclosed |
| Units sold |
Not separately disclosed |
| Product-level operating profit |
Not separately disclosed |
| Product-specific impairment |
Not separately disclosed |
| Reported discontinuation year |
2016 |
| Continuing revenue after discontinuation |
None identified as an active commercial product |
What patents protected Gintuit?
Gintuit’s protection likely depended on a portfolio of patents and know-how covering cellularized scaffolds, cell culture, tissue-engineering methods, matrix composition, and manufacturing processes. Patent protection was not the principal reason for the product’s commercial exit.
A reliable product-specific patent table requires confirmation through patent-family records, assignments, continuations, terminal disclaimers, and expiration calculations. Public FDA and company materials establish the regulatory history, but they do not provide a complete, authoritative list of every patent that may have covered Gintuit. The defensible commercial conclusion is that Gintuit did not face a conventional generic patent challenge before discontinuation.
Were Gintuit patents challenged through Paragraph IV litigation?
No material Paragraph IV challenge is associated with Gintuit. Paragraph IV litigation applies to patents listed in the FDA Orange Book for approved drug products. Gintuit was approved through PMA and was not an Orange Book-listed prescription drug.
A competitor seeking to market a similar tissue-engineered oral product would have faced a new regulatory review, manufacturing validation, clinical evidence requirements, and potential patent or trade-secret issues. It would not have been able to rely on an ANDA-based generic approval pathway.
What is the Orange Book status of Gintuit?
Gintuit has no conventional Orange Book status because it is not an NDA-approved drug. It was approved under the FDA’s medical-device PMA framework.
The regulatory implications are material:
- No Orange Book patent listing.
- No ANDA generic pathway.
- No standard Paragraph IV certification.
- No automatic 30-month stay based on an Orange Book patent challenge.
- No conventional Hatch-Waxman exclusivity analysis.
- No biosimilar interchangeability pathway.
The relevant regulatory barrier for a competitor is PMA approval or another applicable FDA device pathway, depending on the design and claims of the competing product.
Did Gintuit face biosimilar risk?
Gintuit did not face biosimilar risk under the Public Health Service Act framework. Biosimilars are follow-on biological products that reference licensed biologics. Gintuit was not marketed as a conventional BLA-licensed reference biologic.
A competing living-cell scaffold would likely require its own regulatory submission and evidence package. The principal risks were regulatory comparability, manufacturing consistency, cell-source controls, sterility, tissue handling, and clinical performance, not biosimilar substitution.
What litigation and licensing deals affected Gintuit?
No major public patent litigation, Paragraph IV proceeding, or settlement agreement is identified as a material driver of Gintuit’s commercial trajectory. The product’s exit was linked to internal manufacturing and market-adoption problems rather than a public patent settlement or court-ordered launch restriction.
Organogenesis had broader commercial relationships and technology licenses across its regenerative-medicine portfolio. Public disclosures do not establish a separately quantified Gintuit licensing stream or a major third-party royalty burden that determined the product’s fate.
How strong was the Gintuit patent and market position?
Gintuit had a technically differentiated position but a weak commercial position.
| Dimension |
Assessment |
| Regulatory differentiation |
High; one of the few FDA-cleared living cellular products for oral soft-tissue repair |
| Manufacturing barrier |
High; living-cell production and quality control were complex |
| Clinical differentiation |
Moderate; avoided donor-site tissue harvesting |
| Reimbursement strength |
Limited |
| Generic substitution risk |
Low because no ANDA pathway existed |
| Biosimilar risk |
Not applicable |
| Adoption risk |
High |
| Revenue scalability |
Low |
| Long-term commercial durability |
Weak |
| Patent-driven value |
Unclear and secondary to manufacturing economics |
The product’s regulatory and technical barriers did not translate into durable market power. A strong manufacturing moat can become a liability when market volume is too low to support the cost base.
What generic launch scenarios existed for Gintuit?
There was no conventional generic launch scenario. Potential competitive entry would have required one of the following:
- Development of a new acellular or cellular oral-tissue product.
- A new FDA submission based on the competitor’s own device and manufacturing data.
- Use of a different material, such as porcine collagen or acellular human dermis.
- Competition through a lower-cost autologous or synthetic procedure.
The most credible competitive pressure came from clinically acceptable alternatives that were easier to manufacture and distribute, not from a legally substitutable Gintuit copy.
What is the current commercial outlook for Gintuit?
Gintuit has no active commercial growth trajectory. Its market opportunity ended with Organogenesis’ 2016 discontinuation decision. Any residual value is limited to historical technology, know-how, patent-family assets, or potential redevelopment of the cellularized-scaffold platform by an acquirer or successor.
A relaunch would require more than renewed sales activity. It would likely require manufacturing remediation, updated regulatory engagement, renewed clinician adoption, reimbursement support, and evidence that the product can compete economically with established acellular grafts and autologous surgery.
Key Takeaways
- Gintuit was FDA approved on March 9, 2012, under PMA P110013.
- It was a living, allogeneic cellularized scaffold for adult mucogingival conditions.
- Organogenesis discontinued sales and marketing in 2016.
- Manufacturing complexity and limited market adoption were the principal commercial barriers.
- Product-level revenue, margin, volume, and impairment data were not separately disclosed.
- Gintuit had no Orange Book listing and no conventional generic or Paragraph IV pathway.
- Biosimilar substitution was not applicable.
- The product’s technical differentiation did not overcome cost, workflow, reimbursement, and scale constraints.
- Its commercial failure was primarily an execution and market-structure problem, not a loss of patent exclusivity.
FAQs
Was Gintuit a biologic drug or a medical device?
Gintuit was a tissue-engineered product regulated through the FDA’s PMA pathway. It was not marketed through a conventional NDA or BLA pathway.
Is Gintuit still available for dental procedures?
No active commercial availability is identified. Organogenesis discontinued sales and marketing in 2016.
Can a generic manufacturer copy Gintuit?
Not through an ANDA. A competing product would need its own applicable FDA clearance or approval and would face manufacturing, clinical, and intellectual-property barriers.
Did Organogenesis report Gintuit sales separately?
No. Public filings did not disclose a standalone Gintuit revenue or profitability line.
What replaced Gintuit in the periodontal market?
The main alternatives were autologous connective-tissue grafts, acellular dermal matrices, xenogeneic collagen matrices, and other soft-tissue repair materials. No single replacement product replicated Gintuit’s exact living-cell design.
References
-
U.S. Food and Drug Administration. (2012). GINTUIT PMA P110013: Premarket approval database. FDA.
-
Organogenesis Holdings Inc. (2017). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2016. U.S. Securities and Exchange Commission.
-
Organogenesis Holdings Inc. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2017. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. FDA.
